Contribute Try STAT+ Today

Before the pandemic, most people had never heard of Illumina, the California-based sequencing behemoth whose machines generate upwards of 90% of the world’s DNA data. And while Illumina might still not be a household name, over the last 15 months the technology it sells has become standard dinner table fare. Genetic vaccines, coronavirus variants, wastewater surveillance — never before has the world of sequencing spilled over so forcefully into mainstream public consciousness.

“People are talking about mutations and variants, it’s now become part of the public lexicon,” said CEO Francis deSouza said Tuesday at the STAT Health Tech Summit. “I think it’s accelerated the field by maybe five years, because genomics has been instrumental in this pandemic from the very beginning.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.